Lexicon Pharmaceuticals (LXRX) Cut to Underweight at JPMorgan Chase & Co.

Lexicon Pharmaceuticals (NASDAQ:LXRX) was downgraded by stock analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating in a research report issued on Wednesday, The Fly reports.

A number of other analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, January 31st. BidaskClub upgraded shares of Lexicon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, January 20th. ValuEngine cut shares of Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Finally, Wedbush restated an “outperform” rating and issued a $38.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Thursday, November 30th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $28.50.

Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) opened at $9.29 on Wednesday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.66 and a quick ratio of 1.65. The stock has a market cap of $975.63, a P/E ratio of -7.37 and a beta of 0.24. Lexicon Pharmaceuticals has a one year low of $8.07 and a one year high of $18.00.

In other news, Director Public Equities L.P. Invus acquired 180,727 shares of Lexicon Pharmaceuticals stock in a transaction dated Friday, November 17th. The stock was acquired at an average cost of $10.11 per share, for a total transaction of $1,827,149.97. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.77% of the stock is currently owned by insiders.

Hedge funds have recently made changes to their positions in the stock. Quantitative Systematic Strategies LLC bought a new position in Lexicon Pharmaceuticals during the fourth quarter worth $117,000. Aperio Group LLC bought a new position in Lexicon Pharmaceuticals during the fourth quarter worth $127,000. Cubist Systematic Strategies LLC bought a new position in Lexicon Pharmaceuticals during the third quarter worth $149,000. Teacher Retirement System of Texas bought a new position in Lexicon Pharmaceuticals during the fourth quarter worth $161,000. Finally, Parametric Portfolio Associates LLC bought a new position in Lexicon Pharmaceuticals during the second quarter worth $182,000.

ILLEGAL ACTIVITY NOTICE: “Lexicon Pharmaceuticals (LXRX) Cut to Underweight at JPMorgan Chase & Co.” was first published by American Banking News and is owned by of American Banking News. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/14/lexicon-pharmaceuticals-lxrx-cut-to-underweight-at-jpmorgan-chase-co.html.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

The Fly

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply